Graham E, Heltshe S, Magaret A
Contemp Clin Trials Commun. 2024; 42:101378.
PMID: 39678155
PMC: 11639362.
DOI: 10.1016/j.conctc.2024.101378.
Liu C, Fischer J, Alt J, Bodner T, Chowdhury N, Getz A
PLoS One. 2024; 19(9):e0310986.
PMID: 39325787
PMC: 11426423.
DOI: 10.1371/journal.pone.0310986.
Magaret A, Graham E, Caverly L, Cromwell E, Paynter A, Rosenfeld M
J Cyst Fibros. 2024; 23(5):943-946.
PMID: 39147620
PMC: 11410506.
DOI: 10.1016/j.jcf.2024.07.005.
Peterson C, Rao M, Palipana A, Manning E, Vancil A, Ryan P
Sci Total Environ. 2024; 950:175348.
PMID: 39117222
PMC: 11349456.
DOI: 10.1016/j.scitotenv.2024.175348.
Burgel P, Bourge X, Mackosso C, Parquin F
Open Forum Infect Dis. 2024; 11(8):ofae391.
PMID: 39108933
PMC: 11303002.
DOI: 10.1093/ofid/ofae391.
Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis.
Merlo C, Thorat T, DerSarkissian M, McGarry L, Nguyen C, Gu Y
Thorax. 2024; 79(10):925-933.
PMID: 38937105
PMC: 11503052.
DOI: 10.1136/thorax-2023-220558.
Impact of age at ivacaftor initiation on pulmonary outcomes among people with cystic fibrosis.
Merlo C, McGarry L, Thorat T, Nguyen C, DerSarkissian M, Muthukumar A
Thorax. 2024; 79(10):915-924.
PMID: 38719441
PMC: 11503177.
DOI: 10.1136/thorax-2023-220559.
Predicting lung function decline in cystic fibrosis: the impact of initiating ivacaftor therapy.
Zhou G, Wang Z, Palipana A, Andrinopoulou E, Afonso P, McPhail G
Respir Res. 2024; 25(1):187.
PMID: 38678203
PMC: 11056050.
DOI: 10.1186/s12931-024-02794-2.
Social-environmental phenotypes of rapid cystic fibrosis lung disease progression in adolescents and young adults living in the United States.
Palipana A, Vancil A, Gecili E, Rasnick E, Ehrlich D, Pestian T
Environ Adv. 2023; 14.
PMID: 38094913
PMC: 10718514.
DOI: 10.1016/j.envadv.2023.100449.
Respiratory system parameters in children with low severity cystic fibrosis: is there early involvement in relation to healthy peers?.
Ducati G, Cardoso J, Ferrazeane E, Schivinski C
Rev Paul Pediatr. 2023; 42:e2023030.
PMID: 38088678
PMC: 10712943.
DOI: 10.1590/1984-0462/2024/42/2023030.
A systematic review of the clinical impact of small colony variants in patients with cystic fibrosis.
Ryan H, Ballard E, Stockwell R, Duplancic C, Thomson R, Smith K
BMC Pulm Med. 2023; 23(1):323.
PMID: 37658311
PMC: 10474644.
DOI: 10.1186/s12890-023-02611-4.
Risk factors for forced expiratory volume in 1 s decline in European patients with cystic fibrosis: data from the European Cystic Fibrosis Society Patient Registry.
Hatziagorou E, Fieuws S, Orenti A, Naehrlich L, Krivec U, Mei-Zahav M
ERJ Open Res. 2023; 9(3).
PMID: 37483280
PMC: 10359040.
DOI: 10.1183/23120541.00449-2022.
DYNAMIC RISK PREDICTION TRIGGERED BY INTERMEDIATE EVENTS USING SURVIVAL TREE ENSEMBLES.
Sun Y, Chiou S, Wu C, McGarry M, Huang C
Ann Appl Stat. 2023; 17(2):1375-1397.
PMID: 37284167
PMC: 10241448.
DOI: 10.1214/22-aoas1674.
Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist.
Nichols D, Morgan S, Skalland M, Vo A, Van Dalfsen J, Singh S
J Clin Invest. 2023; 133(10).
PMID: 36976651
PMC: 10178839.
DOI: 10.1172/JCI167957.
Built environment factors predictive of early rapid lung function decline in cystic fibrosis.
Gecili E, Brokamp C, Rasnick E, Afonso P, Andrinopoulou E, Dexheimer J
Pediatr Pulmonol. 2023; 58(5):1501-1513.
PMID: 36775890
PMC: 10121820.
DOI: 10.1002/ppul.26352.
Clinical outcomes of adults and children with cystic fibrosis during the COVID-19 pandemic.
Doumit M, Chuang S, Middleton P, Selvadurai H, Sivam S, Ruseckaite R
J Cyst Fibros. 2022; 22(3):581-586.
PMID: 36163166
PMC: 9477965.
DOI: 10.1016/j.jcf.2022.09.006.
Persistent Aspergillus fumigatus infection in cystic fibrosis: impact on lung function and role of treatment of asymptomatic colonization-a registry-based case-control study.
Blomquist A, Inghammar M, Al Shakirchi M, Ericson P, Krantz C, Svedberg M
BMC Pulm Med. 2022; 22(1):263.
PMID: 35790954
PMC: 9258124.
DOI: 10.1186/s12890-022-02054-3.
Primary ciliary dyskinesia in Volendam: Diagnostic and phenotypic features in patients with a CCDC114 mutation.
Kos R, Israels J, van Gogh C, Altenburg J, Diepenhorst S, Paff T
Am J Med Genet C Semin Med Genet. 2022; 190(1):89-101.
PMID: 35343062
PMC: 9314105.
DOI: 10.1002/ajmg.c.31968.
Serum anti-PAD4 autoantibodies are present in cystic fibrosis children and increase with age and lung disease severity.
Linnemann R, Yadav R, Zhang C, Sarr D, Rada B, Stecenko A
Autoimmunity. 2022; 55(2):109-117.
PMID: 35199621
PMC: 9996683.
DOI: 10.1080/08916934.2021.2021193.
Seasonal variation of lung function in cystic fibrosis: longitudinal modeling to compare a Midwest US cohort to international populations.
Gecili E, Brokamp C, Palipana A, Huang R, Andrinopoulou E, Pestian T
Sci Total Environ. 2022; 776.
PMID: 35125553
PMC: 8813005.
DOI: 10.1016/j.scitotenv.2021.145905.